News
Cel-Sci Corpn to commence Phase III trial of MultiKine in Head and Neck Cancer
Phase III study to commence for MultiKine from Cel-SciCorpn. in third quarter of 2010 being the largest Head and Neck Cancer trial ever
MultiKine,cancer immunotherapy ,is being given to treatment naive patients before surgery/radiation or chemotherapy as it is best to stimulate an anti tumour immune response while the immune system is still competent. Cel-Sci are partnered with Teva Pharma and Orient Europharma. MultiKine is considered the first in a new class of immune simulators.
Condition: Head & Neck Cancer
Type: drug